Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Re:I Contacted Cliff ..Weak leadership leads to this kind of result
22
Nov 19, 2012 02:36PM
1
Nov 19, 2012 02:50PM
2
Nov 19, 2012 02:57PM
4
Nov 19, 2012 04:17PM
1
Nov 19, 2012 04:21PM
1
Nov 19, 2012 04:21PM
6
Nov 19, 2012 04:38PM
2
Nov 19, 2012 06:52PM
2
Nov 19, 2012 09:44PM
8
Nov 20, 2012 02:44AM
10
opc
Nov 20, 2012 02:49AM
4
Nov 20, 2012 06:40AM
6
Nov 20, 2012 10:14AM
5
Nov 20, 2012 10:20AM
24
Nov 20, 2012 11:27AM
4
Nov 20, 2012 11:45AM
3
Nov 20, 2012 02:01PM

Another license is no longer a 'Material' event. It is a normal and expected event. To be 'Material' it would have to outstanding and possible have a dramatic effect on the company's future. Frankly they are not required to even report it on the web site.

All they are 'required' to do in record and report the income on the quarterly report.

So they draft language that makes licensing a normal and expected event so they dont have to disclose it to us. If it is so normal and expected why do we get just a few signings per year. It is our only source of income that we have given away to to a private company without the knowledge of a signing everyone that does know about the signing can trade on this knowledge. This is a public company they can't contract out of the legal disclosures. Also we have integrity problems with our leaders and our private partner where the money seems to never make it to our bottomline because of commingling, overcharging and fraud. I would say that every license is a material event and we should be notified before the next market opening. Unfortunately we have to be the watchdogs for PTSC over TPL because it seems that our BOD is unwilling or incapable of that task.

22
Nov 21, 2012 09:49AM
3
Nov 21, 2012 10:39AM
2
Nov 21, 2012 11:23AM
5
Nov 21, 2012 12:51PM
5
Nov 21, 2012 01:07PM
4
Nov 26, 2012 01:38PM
Share
New Message
Please login to post a reply